This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Therapeutic Antibody Hybridoma Platform
BioVenic operates a mature hybridoma platform to achieve efficient production of highly specific veterinary monoclonal antibodies. Our services cover the full workflow from initial antigen preparation and animal immunization to strict screening and identification to fulfill clients' research requirements. Hybridoma cell lines are generated by fusing antigen-stimulated mouse B lymphocytes with myeloma cells. Subsequent screening of hybridoma cells allows researchers to isolate clones that secrete monoclonal antibodies targeting specific antigenic epitopes.
Fig.1 Process for the preparation of monoclonal antibodies using a hybridoma technology platform.1,3
Antigen Preparation
BioVenic provides various types of antigen preparation services to meet requirements. The higher antigen purity used to prepare the monoclonal antibody, the higher the success rate of the monoclonal antibody preparation.
| Proteins | Peptides | DNA | mRNA | VLP |
Animal Immunization
Animal immunization is no one-size-fits-all approach, BioVenic conducts a thorough analysis of the characteristics of target antigens. We consider various factors such as the nature of the antigen, the immunization route, and its immunogenicity to tailor a personalized animal immunization plan. Here are the adjustment items of the animal immunization protocol.
| Antigen Dosage | Immunization Frequency | Adjuvant Use |
Cell Fusion
BioVenic provides PEG fusion services, ensuring excellent fusion results by rigorously controlling the concentration, molecular weight, and exposure time of PEG to samples. BioVenic also offers electrofusion services. We have introduced advanced electrofusion equipment, and key factors for successful electrofusion, such as electric field strength, pulse number, and pulse duration, all adjusted within a range by our professionals.
PEG Fusion
Polyethylene glycol (PEG) can lead to cellular dehydration and changes in cell membrane structure, resulting in the fusion of myeloma cells and mouse B lymphocytes. This substance is easy to prepare, stable in nature, and convenient to use.
Electrofusion
As a physical method, electrofusion technology offers high fusion efficiency, low cell toxicity, and the absence of chemical substances and viruses. It utilizes an electric field to connect cells in series, followed by the application of momentary high-voltage pulses to induce reversible electroporation of the cell membranes, thereby promoting cell fusion.
Hybridoma Cell Screening
Various fusion outcomes are generated after fusion, including unfused cells, self-fused cells, and correctly fused hybridoma cells. BioVenic provides hybridoma cell screening services to obtain the correct cells. We utilize HAT medium, which contains hypoxanthine, aminopterin, and thymidine, for cell screening, only the fused hybridoma cells can proliferate indefinitely in HAT medium. Our professional staff used limiting dilution analysis to serially dilute the hybridoma cells. We test whether the antibodies secreted by the cells in the supernatant of each well can bind to specific antigens. This process is repeated multiple times until it ensures that each well's proliferating cells are monoclonal.
Monoclonal Antibody Production
Using hybridoma cell technology to produce monoclonal antibodies for veterinary use, BioVenic offers two primary methods, ascites production and in vitro culturing. Our expertise in these methods ensures that clients receive high-quality, specific monoclonal antibodies for their development projects.
Ascites Production
Hybridoma cells are implanted into the peritoneal cavity of mice, leading to ascites production containing substantial amounts of monoclonal antibodies. This approach enables the rapid generation of a large quantity of veterinary monoclonal antibodies. BioVenic provides a high-quality animal housing environment and skilled personnel to ensure animal welfare.
In Vitro Culturing
In vitro culturing involves culturing selected hybridoma cells in a suitable growth medium. BioVenic has introduced high-capacity bioreactors capable of high-density culturing of hybridoma cells. Additionally, we offer cell conditioning services using low or serum-free culture media to reduce impurities in the final product, while also addressing concerns related to animal-derived contamination and animal welfare.
Antibody Engineering
Mouse-derived antibodies used in target animals such as canine and feline may exhibit significant heterogeneity. This may not only lead to suboptimal therapeutic efficacy but may also pose safety concerns. BioVenic offers antibody caninization and felinization services to reduce antibody immunogenicity. We also offer affinity maturation services to maintain potentially reduced antibody affinity.
Why Choose Us?
A one-stop veterinary therapeutic antibody development service utilizing hybridoma technology for a more convenient experience.
Provides highly specific antibody production services to ensure consistent affinity and specificity.
Customized design and optimization of antibodies according to specific needs.
Related Research
Published work compared three mainstream monoclonal‑antibody discovery pipelines for veterinary applications. Hybridoma technology depends on myeloma‑B‑cell fusion, featuring months‑long workflows, low fusion efficiency and risks of clone genetic instability. Phage‑display supports high‑throughput library screening yet generates artificial heavy‑light‑chain pairing. By contrast, single‑B‑cell approaches isolate antigen‑specific primary B cells via FACS sorting to capture natively paired antibody sequences, shortening the whole discovery cycle down to weeks and preserving in‑vivo‑matured antibody affinity.
Fig.2 Comparative analysis of monoclonal antibody discovery platforms.2,3
Frequently Asked Questions
What types of antigen raw materials can be used to initiate hybridoma monoclonal antibody preparation?
Our platform supports multiple antigen forms for immunization, including purified proteins, short synthetic peptides, DNA plasmids, mRNA, and virus-like particles (VLPs). Higher antigen purity effectively improves the success rate of positive hybridoma clone screening in subsequent steps.
What two cell fusion technologies do you provide for hybridoma construction, and what are their respective advantages?
We supply PEG chemical fusion and electrofusion. PEG fusion is low-cost, stable and easy to operate for conventional projects. Electrofusion adopts physical electric pulse stimulation, featuring higher fusion efficiency, low cell toxicity and no residual chemical reagents, suitable for high-difficulty antigen immunization projects.
How does HAT selective medium filter out valid hybridoma clones after cell fusion?
Unfused myeloma cells, unfused B cells and self-fused cells cannot survive long-term culture in HAT medium containing hypoxanthine, aminopterin and thymidine. Only successfully fused hybridoma cells possess complementary metabolic pathways to proliferate stably, laying the foundation for subsequent positive antibody screening.
What two scalable production methods are available after obtaining positive hybridoma cell lines?
Two mature production routes are supported: in vivo mouse ascites preparation for fast, large-volume antibody acquisition. And serum-free bioreactor in vitro cell culture, which avoids animal-derived impurities and meets high-purity antibody requirements while complying with animal welfare standards.
What customized adjustments can be made to the animal immunization scheme for difficult low-immunogenicity antigens?
We flexibly adjust three core immunization parameters based on antigen properties: optimized antigen injection dosage, adjusted immunization cycle frequency, and matched immune adjuvant combinations, to enhance antigen immunogenicity and boost the generation of target-specific B lymphocytes in mice.
Partner with BioVenic
Hybridoma technology, as one of the classic methods for veterinary monoclonal antibody development, has been successfully applied in numerous projects. BioVenic has established the veterinary therapeutic antibody hybridoma platform to provide services for developing high-quality veterinary therapeutic antibodies using hybridoma technology. If you have such needs, please don't hesitate to contact us!
References
- Saeed, Abdullah FUH, et al. "Antibody engineering for pursuing a healthier future." Frontiers in microbiology 8 (2017): 495. https://doi.org/10.3389/fmicb.2017.00495
- Shi, Pengfei, et al. "Leveraging single B cell antibody platforms to develop countermeasures against animal viral diseases: recent advances and future perspectives." Frontiers in Veterinary Science 13 (2026): 1854176. https://doi.org/10.3389/fvets.2026.1854176
- Distributed under Open Access license CC BY 4.0, without modification.